GlassScriptPhysician profile
Alexis Adeojo
NPI 1336823095
$3,839.49
in general payments reported to CMS, 2019-2025
20 companies · $2,543 in 2025
The $2,543 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $164 · 2024: $1,132 · 2025: $2,543.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705 · Education: $135.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.54 |
| Education | $134.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $669.28 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $525.06 | 2023-2025 | Skyrizi |
| Gilead Sciences, INC. | $304.60 | 2025 | Vemlidy, Livdelzi |
| Madrigal Pharmaceuticals | $254.93 | 2025 | Rezdiffra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $213.53 | 2024-2025 | Xifaxan, Trulance |
| Lilly USA, LLC | $208.47 | 2024-2025 | Omvoh, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $207.31 | 2024-2025 | Entyvio, Eohilia |
| Aimmune Therapeutics, INC. | $194.64 | 2024-2025 | Zenpep |
| Genzyme Corporation | $184.53 | 2023-2025 | |
| Ardelyx, INC. | $182.54 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $169.51 | 2024-2025 | Sucraid, Sucraid |
| Pfizer INC. | $155.23 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $151.32 | 2024-2025 | Dupixent |
| Phathom Pharmaceuticals, INC. | $124.14 | 2023-2025 | Voquezna |
| Novo Nordisk INC | $95.82 | 2025 | Wegovy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $78.08 | 2024-2025 | |
| Medtronic, INC. | $46.02 | 2024 | Interstim |
| Ipsen Biopharmaceuticals, INC | $38.19 | 2025 | Iqirvo |
| Orphalan INC | $18.49 | 2025 | Cuvrior |
| Ironwood Pharmaceuticals, INC | $17.80 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexis Adeojo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.